Venky’s (India) Ltd Q3 FY26 – ₹960 Cr Revenue, 138% PAT Growth, but 41x P/E for a Chicken With 2.5% Margins
1. At a Glance – Chicken, Cash, and Confusion
Venky’s (India) Ltd is currently valued at ₹2,115 crore, trading at ₹1,502, with a 41.3x P/E multiple for a business that runs on 2.53% operating margins and a ROE of 8.21%. Let that sink in. This is not a SaaS startup selling vibes — this is chicken, eggs, soya, and veterinary medicines.
Q3 FY26 numbers look spicy on the surface: Revenue ₹960 crore, PAT ₹48.6 crore, 138% YoY profit growth, and EPS ₹34.48 for the quarter. Sounds like a comeback? Maybe. But zoom out and you’ll notice 5-year sales growth of 0.28%, 3-year sales CAGR of –9%, and stock returns that have gone absolutely nowhere for half a decade.
Debt is under control at ₹181 crore with Debt/Equity of 0.13, promoter holding is steady at 56.11%, and there is zero promoter pledge. Balance sheet isn’t scary. The valuation? That’s where the chicken starts sweating.
So the big question before we even begin: Is Venky’s finally breaking out of its cyclic poultry curse, or is this just another temporary wing-flap before gravity wins again?
2. Introduction – The OG Chicken King With PTSD From Cycles
Venky’s is not a new kid. This company has been around long enough to have survived bird flu, feed inflation, COVID logistics chaos, and every poultry boom-bust cycle known to Indian capitalism.
The VH Group runs a fully integrated poultry ecosystem — breeding, hatching, feed, processing, branding, exports, and even veterinary medicines. On paper, this is exactly what MBA textbooks love. Vertical integration. Control over supply chain. Scale. Brand recall.
And yet… profits behave like a roller coaster after too much Red Bull.
Why? Because poultry is a brutal business. Feed costs swing. Chicken prices collapse without warning. Demand is emotional, seasonal, and sometimes political. Margins are thin even in good years. One bad quarter can erase two good ones.
Q3 FY26 looks strong because Q3 FY25 was ugly (loss-making). So YoY growth looks heroic. But QoQ? That’s where reality quietly clears its throat.
Venky’s story has always been about survival and optionality, not smooth compounding. The market, however, is currently pricing it like a reformed monk who has renounced volatility forever.
Has that really happened? Let’s dissect the bird.
3. Business Model – WTF Do They Even Do?
Think of Venky’s as India’s chicken ecosystem operator, not just a frozen nuggets brand.
Poultry & Poultry Products
This is the heart of the empire. They produce:
Day-old broiler & layer chicks
SPF eggs (they’re one of the largest producers in Asia)
They source elite parent chicks through JV arrangements with global genetics leaders, ensuring control over quality and yield. This matters a lot in poultry, where genetics decide profitability before the bird is even born.
Animal Health Products
This is the quiet, underrated vertical. Venky’s manufactures veterinary medicines and poultry supplements. In FY24, they commissioned a new manufacturing unit at Kesurdi, Maharashtra, now commercially operational:
Powders: 600 tonnes/year
Liquids: 300 KL/year
This segment is less cyclical than poultry meat and has better margin stability. Management has guided Animal Health revenue at ₹370–380 crore in FY26.
Oilseed (Soya Processing)
Venky’s operates three soya plants in Maharashtra with 5.4 lakh MTPA capacity. This segment helps partially hedge feed input risks, but margins here are also cyclical and commodity-driven.
In short: Venky’s doesn’t sell chicken. Venky’s manages biological volatility for a living.
4. Financials Overview – Numbers That Cluck Loudly
Quarterly Comparison Table (₹ crore)
Metric
Latest Qtr (Q3 FY26)
YoY Qtr (Q3 FY25)
Prev Qtr (Q2 FY26)
YoY %
QoQ %
Revenue
960
882
801
8.9%
19.9%
EBITDA
70
29
-31
141%
NA
PAT
48.6
20
-27
138%
NA
EPS (₹)
34.48
14.47
-18.83
138%
NA
Witty but accurate commentary: Yes, profits exploded YoY. But that’s because last year the chicken was on a ventilator. QoQ recovery is real, but margins are still single-digit. This is not a structural margin expansion story yet.
